Senior Software Engineer
Molecular Simulations Lead
Associate Director, Biology
Scientific Engineering Fellow
Executive Director, Immunology and Translational Research
Associate Director, Structural Biology
Scientist II
Senior Associate Scientist
Immunology Lead, Scientific Director
Senior Research Associate
Staff Software Engineer
Executive Assistant
Senior Director, Computational Chemistry
Director, Medicinal Chemistry
Senior Scientist, Structural Biology and Biophysics
Scientist I, Molecular Simulations
Principal Scientist, Computational Chemistry
Senior Scientist
Data Science Lead
Associate Director, Engineering
Senior DevOps Engineer
Principal Scientist, Structural Biology and Biophysics
Immunology Lead, Scientific Director
Our board offers strategic guidance built on decades of experience in biotechnology, drug development, finance and company building. The directors have proven track records of advancing novel therapeutics to approval. They bring deep operational leadership from both public and private biotech companies, along with expertise in financing, partnerships and global drug commercialization. They also provide stewardship for high-growth research and development organizations. Their leadership positions PsiThera’s platform and programs for scientific excellence and long-term success.
President and Chief Executive Officer, PsiThera
Founder and Managing General Partner, Samsara Biocapital
Partner, Lightstone Ventures
EVP, Roivant Health
Venture Partner, Samsara Biocapital
Our Scientific Advisory Board brings together distinguished leaders in computational chemistry, immunology, translational science, and biotech company building. These individuals bring deep domain expertise and proven success in advancing breakthrough therapeutics for patients. This group plays a central role in shaping PsiThera’s scientific and strategic trajectory. They rigorously challenge and validate our core hypotheses, contribute cutting-edge insights into protein structure, function, and immune signaling in addition to advising on experimental design, model development, and platform evolution. Beyond scientific guidance, the SAB provides strategic perspective on competitive positioning, clinical relevance, and value creation across our pipeline. Their multidimensional expertise ensures PsiThera remains at the forefront of mechanism-driven drug design while advancing programs with the rigor, clarity, and translational potential needed to make a meaningful impact on patient care.
Professor of Chemistry and Photon Sciences; Stanford University
Chief Executive Officer; Spica Therapeutics
Chief Executive Officer; IFM Therapeutics
President, Research and Development; Nimbus Therapeutics
Professor and Division of Molecular Internal Medicine; University Hospital of Würzburg
PsiThera’s Open Science Fellows program links the company with leading academic researchers at the forefront of quantum mechanics, molecular dynamics, statistical thermodynamics, machine learning and simulation science. Working within an open-science framework, the fellows collaborate with PsiThera teams to develop new methods and tools. They co-create technologies that improve accuracy, sampling and predictive modeling, and they help connect foundational research to real-world drug discovery. The program advances a shared mission to make high-performance computational methods accessible and impactful. By maintaining strong ties to the global scientific community, PsiThera continues to push the limits of computational and physical possibilities.
Associate Professor (Without Tenure); Massachusetts Institute of Technology
Professor; Brooklyn College of the City University of New York
Vice Chair, Professor; University of California, Irvine
Chief Scientist, OpenADMET; Strategic Advisor, PsiThera